treatment

97

97

97. That’s my latest CD4+ count, less than half the count from six weeks ago.

That’s it. I have tried as many alternative treatments as I can think of to reverse the decline. I will be starting my third round of pharmaceutical ARVs as soon as I can get a prescription and fill it.

This decision has been a long time coming, and in hindsight, I probably should have restarted a few months ago. There’s nothing magical about 97, or being below 100, but it’s as good a breaking point as any. I’ve long argued that there are two things to keep in mind about CD4 counts: one is the long-term trend; the other is single- or low double-digit counts.

Reduce AIDS drug toxicity and side effects

Reduce AIDS drug toxicity and side effects

I embarked on my third course of ARVs since 1998. For ten of the sixteen years I have been HIV-positive, I was able to manage well enough without ARVs and I continue to believe there is no reason for otherwise healthy HIV-positive—let alone negative—gay men to take these drugs. To those who want to wave a recent study about the benefits of early intervention in my face, I would ask them why they put so much faith in a science that has utterly failed us to date.

Pharmaceutical solutions to AIDS are not enough

A recent phone conversation with a friend is helping me to continue to refine what I want to focus on as an AIDS dissident activist. In a passionate outburst that revealed a new side of his character, he blurted out his dismay that our society in general and our gay community in particular seems to be willing to settle for a solution to AIDS that relies exclusively on drugs from the pharmaceutical industry.

Dr. Jacques Leibowitch: 4 days a week is enough!

Dr. Jacques Leibowitch: 4 days a week is enough!

In the simplest possible summation, Leibowitch has been treating HIV-positive patients with traditional ARV cocktails, called HAART. Where he leaves the path of traditional treatment guidelines is that once a patient is “stabilised”—meaning they have achieved respectably high CD4 counts, and their viral load is undetectable for six months—Leibowitch starts reducing the number of days per week that a patient takes these drugs, to as little as twice per week.

Higher CD4 count increases risk of ARV adverse effects

Higher CD4 count increases risk of ARV adverse effects

Each patient fell into one of three groups: <350 CD4 cells/muL; 351-499; and >500. This last group would be considered “normal” according to AIDS.gov, which lists the range for CD4 counts as 500-1000. Yet, according to this study, this group of so-called “healthy” patients were almost one and a half times more likely to experience a drug-related adverse effect.

The report reinforces another point that I find I must continue to drive home over and over again, and that is the definition of “low CD4 counts”.

Borg ship

AIDS drugs: when resistance is futile

In nearly every conversation I’ve had with Affecteds who are experimenting with ways to reduce the toxicity of antiretroviral (ARV) regimens, questions about “AIDS drug resistance” comes up. Resistance is often raised as a boogeyman in research trials of monotherapy and intermittent treatment options. While drug resistance—especially bacterial antibiotic resistance to staphylococcus or tuberculosis, for example—is increasingly a problem in modern medicine, one is unlikely to hear drug resistance discussed quite the way it is with AIDS. No other pathogen is described as “sneaky”, “clever”, or more mutable than HIV, despite the fact that retroviruses do not even meet most definitions for being a living entity, let alone have a brain.

No! Nukes!!

AIDS drug guidelines: Stop the nukes!

Stop the nukes! No, not nuclear weapons. Well, yes, those too, but today I’m writing about the increase in reports I’m seeing from the AIDS drug medical literature calling for an end to the use of nucleoside(tide) reverse transcriptase inhibitors (NRTIs), not-so-ironically referred to as “nukes”. As I have written previously, there have been rumblings from clinicians and researchers in the medical literature since at least 2010 to get rid of the NRTI class of antiretroviral drugs entirely from treatment guidelines.

Unfortunately, it is unlikely that this change will occur at anything comparable to the speed with which AZT and other poison pills were “fast-tracked” to market more than 25 years ago.

Homemade yogurt

Rethinking MAF 314

One of the most vexing issues I’ve had to deal with since I started exploring alternatives to ART (antiretroviral therapy) for keeping my immune system as healthy as I can, is my inability to abide by some of the most basic rules of scientific research. I’m not beating myself up too much for this…

Image of Willy Wonka: "Taking fistfuls of toxic drugs won't shorten your lifespan? Tell me again how that works."

Planting memes

Rarely a day goes by that I do not scan the headlines collected from various blogs and sources by Google Reader. Smashing a recent lull in AIDS news, some pretty outrageous headlines have been breaking through lately. Last week, it was Baby AZeTa, the little girl in Mississippi who researchers claimed was cured of…

The end of AZT?

The end of AZT?

As I spend time this week with one of my dearest friends, a man who has been HIV-positive since at least 1987, and who has been on ARVs almost continuously since 1990, I am reminded that Affecteds have always had the option to consider alternatives to conventional pharmaceutical treatment. Last night we recalled some…